A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

SM, Francque; P, Bedossa; V, Ratziu; QM, Anstee; E, Bugianesi; AJ, Sanyal; R, Loomba; SA, Harrison; R, Balabanska; L, Mateva; N, Lanthier; N, Alkhouri; C, Moreno; JM, Schattenberg; D, Stefanova-Petrova; L, Vonghia; R, Rouzier; M, Guillaume; A, Hodge; M, Romero-Gómez; P, Huot-Marchand; M, Baudin; MP, Richard; JL, Abitbol; P, Broqua; JL, Junien; MF, Abdelmalek

doi:10.1056/nejmoa2036205

Public

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

Shared by NobleBlocks on Oct 1, 2021 • 12:00 AM UTC

Authors:

Francque SM

Bedossa P

Ratziu V

Abstract

Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH.Methods In this phase 2b, double-bli...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!